Risk stratification in luminal-type breast cancer: Comparison of Ki-67 with EndoPredict test results

Risk stratification in luminal-type breast cancer: Comparison of Ki-67 with EndoPredict test results

Objectives: Adjuvant chemotherapy decision in patients with hormone receptor positive, HER2 negative breast cancer (BC) is challenging. Ki-67 is widely used for adjuvant therapy decision in BC. The multigene assay EndoPredict (EP) has shown to provide valid and additional information about the risk...

Full description

Bibliographic Details
Main Authors: Aurelia Noske, Sophie-Isabelle Anders, Johannes Ettl, Alexander Hapfelmeier, Katja Steiger, Katja Specht, Wilko Weichert, Marion Kiechle, Evelyn Klein
Format: Article
Language:English
Published: Elsevier 2020-02-01
Series:Breast
Subjects:
Breast cancer
Luminal-type
Risk stratification
EndoPredict
Ki-67
Online Access:http://www.sciencedirect.com/science/article/pii/S096097761930596X

Similar Items

Similar Items